Ascendis Pharma A (ASND) Change in Account Payables (2014 - 2026)
Ascendis Pharma A (ASND) posted Change in Account Payables of -$24.6 million for Q1 2026, down 130.03% sequentially from -$10.7 million in Q4 2025, and up 42.53% YoY from -$17.3 million in Q1 2025.
Ascendis Pharma A (ASND) Change in Account Payables (2014 - 2026) Analysis & Trends
Ascendis Pharma A has reported Change in Account Payables for 13 years, with the latest figure at -$24.6 million in Q1 2026.
- Quarterly Change in Account Payables rose 42.53% year-over-year to -$24.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$26.9 million (down 540.89% YoY) and the FY2025 annual result came in at -$49.2 million, down 270.85% from the prior year.
- Change in Account Payables fell to -$24.6 million in Q1 2026 per ASND's latest filing, from -$10.7 million in the prior quarter.
- Over five years, Change in Account Payables peaked at $48.1 million in Q4 2024 and troughed at -$42.9 million in Q1 2025.
- A 5-year average of $535476.0 and a median of -$4.9 million in 2022 frame the typical range for Change in Account Payables.
- The widest YoY moves for Change in Account Payables: up 544.5% in 2024, down 275.44% in 2024.
- Over 5 years, Change in Account Payables stood at $23.9 million in 2022, then sank by 145.28% to -$10.8 million in 2023, then jumped by 544.5% to $48.1 million in 2024, then sank by 122.28% to -$10.7 million in 2025, then sank by 130.03% to -$24.6 million in 2026.
- According to Business Quant data, Change in Account Payables over the past three periods registered -$24.6 million, -$10.7 million, and -$8.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -66.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 5.03 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 37.53 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 520,137.79 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Ascendis Pharma A | 15.40 Bn | 14.73 Bn | 268.20 Mn | -24.65 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -24.65 Mn |
| Mar 31, 2026 | -24.65 Mn |
| Dec 31, 2025 | -10.71 Mn |
| Dec 31, 2025 | -10.71 Mn |
| Sep 30, 2025 | -8.80 Mn |
| Sep 30, 2025 | -8.80 Mn |
| Jun 30, 2025 | 17.22 Mn |
| Jun 30, 2025 | 17.22 Mn |
| Mar 31, 2025 | -42.88 Mn |
| Mar 31, 2025 | -42.88 Mn |
| Dec 31, 2024 | 48.08 Mn |
| Dec 31, 2024 | 48.08 Mn |
| Sep 30, 2024 | -8.19 Mn |
| Sep 30, 2024 | -8.19 Mn |
| Jun 30, 2024 | 9.10 Mn |
| Jun 30, 2024 | 9.10 Mn |
| Mar 31, 2024 | -20.67 Mn |
| Mar 31, 2024 | -20.67 Mn |
| Dec 31, 2023 | -10.82 Mn |
| Dec 31, 2023 | -10.82 Mn |